Marcel Kuiper

Marcel Kuiper

Auto-generated profile, based on publicly available information

Marcel Kuiper

Centre Jean Perrin

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1999 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JGJoanna Galea-Lauri
Joanna Galea-Lauri
DDDavid Darling
David Darling
SGShu Uin Gan
Shu Uin Gan
LKLeonid Krivochtchapov
Leonid Krivochtchapov
MKMarcel Kuiper
Marcel Kuiper
FFFarzin Farzaneh
Farzin Farzaneh
The ability of NK cells to kill tumor cells is controlled by a balance between activating and inhibitory signals transduced by distinct receptors. In murine tumor models, the costimulatory molecule B7.1 not only acts as a positive trigger for NK-mediated cytotoxicity but can also overcome negative signaling transduced by MHC class I molecules. In this study, we have evaluated the potential of human B7.1-CD28 interaction as an activating trigger for human blood NK cells. Using multiparameter flow cytometric analysis and a panel of different CD28 mAbs, we show that human peripheral blood NK cells (defined by CD56+, CD16+, and CD3− surface expression) express the CD28 costimulatory receptor, with its detection totally dependent on the mAb used. In addition, the level of CD28 varies among individuals and on different NK cell lines, irrespective of CD28 steady-state mRNA levels. By performing Ab binding studies on T cells, our data strongly suggest that binding of two of the anti-CD28 Abs (clones 9.3 and CD28.2) is to a different epitope to that recognized by clones L293 and YTH913.12, which is perhaps modified in the CD28 molecule expressed by the NK cells. We also show that B7.1 enhances the NK-mediated lysis of NK-sensitive but not of NK-resistant tumor cells and that this increased lysis is dependent on CD28-B7 interactions as shown by the ability of Abs to block this lysis. Coculture of the B7.1-positive NK-sensitive cells also led to the activation of the NK cells, as determined by the expression of CD69, CD25, and HLA class II.

24 September 2002 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
MKMarcel Kuiper
Marcel Kuiper
RSRaquel M. Sanches
Raquel M. Sanches
JWJames A. Walford
James A. Walford
NSNigel K.H. Slater
Nigel K.H. Slater

10 January 2018 in Biotechnology Journal
Verified
Journal Article
Open access
PDF file
SGStephen Goldrick
Stephen Goldrick
KLKenneth Lee
Kenneth Lee
CSChristopher Spencer
Christopher Spencer
WHWilliam Holmes
William Holmes
MKMarcel Kuiper
Marcel Kuiper
SFSuzanne S. Farid
Suzanne S. Farid
Glucose control is vital to ensure consistent growth and protein production in mammalian cell cultures. The typical fed‐batch glucose control strategy involving bolus glucose additions based on infrequent off‐line daily samples results in cells experiencing significant glucose concentration fluctuations that can influence product quality and growth. This study proposes an on‐line method to control and manipulate glucose utilizing readily available process measurements. The method generates a correlation between the cumulative oxygen transfer rate and the cumulative glucose consumed. This correlation generates an on‐line prediction of glucose that has been successfully incorporated into a control algorithm manipulating the glucose feed‐rate. This advanced process control (APC) strategy enables the glucose concentration to be maintained at an adjustable set‐point and has been found to significantly reduce the deviation in glucose concentration in comparison to conventional operation. This method has been validated to produce various therapeutic proteins across cell lines with different glucose consumption demands and is successfully demonstrated on micro (15 mL), laboratory (7 L), and pilot (50 L) scale systems. This novel APC strategy is simple to implement and offers the potential to significantly enhance the glucose control strategy for scales spanning micro‐scale systems through to full scale industrial bioreactors.

1 November 2000 in Journal of Controlled Release
Verified
Journal Article
Closed access
MEM.E Eccleston
M.E Eccleston
MKM Kuiper
M Kuiper
FGF.M Gilchrist
F.M Gilchrist
NSN.K.H Slater
N.K.H Slater

17 September 2009 in Biotechnology Letters
Verified
Journal Article
Closed access
PDF file
NSN. J. Silk
N. J. Silk
SDS. Denby
S. Denby
GLG. Lewis
G. Lewis
MKM. Kuiper
M. Kuiper
DHD. Hatton
D. Hatton
GLGary Lye
Gary Lye

1 March 1997 in Human Gene Therapy
Verified
Journal Article
Closed access
JGJoop A. Gäken
Joop A. Gäken
SHSimon J. Hollingsworth
Simon J. Hollingsworth
WHWilliam J. R. Hirst
William J. R. Hirst
ABAndrea G. S. Buggins
Andrea G. S. Buggins
JGJoanna Galea-Lauri
Joanna Galea-Lauri
DDDavid C. Darling
David C. Darling
Previous studies have shown that expression of the immune co-stimulator B7.1 reduces the tumorigenicity of some, but not all, malignant cell lines. However, B7.1-expressing tumor cells are not very effective in inducing the rejection of established tumors. This may in part be due to induction of anergy in the potentially reactive T cells. Previous studies have shown that IL-2 can reverse the anergic state both in vitro and in vivo. Therefore, we have examined the effect of retrovirus-mediated delivery and expression of murine B7.1 and interleukin-2 on tumor formation and rejection of established MHC class I+/II¯ NC adenocarcinomas. Neither the expression of B7.1 nor IL-2 alone had a significant effect on NC tumorigenicity. In contrast, combined expression of B7.1 and IL-2 substantially decreased the tumorigenicity of these cells in the immune-competent syngeneic hosts. T-cell depletion studies show this to be dependent primarily on the activation of CD4+ cells. Furthermore, distant subcutaneous injection of irradiated NC/IL-2/B7.1 can induce, much more effectively than NC/B7.1 or NC/IL-2, the rejection of small NC tumors, and prevent the recurrence of large surgically resected tumors. Together, these results suggest that tumor cells genetically modified to express B7.1 and IL-2 can induce the immune-mediated rejection of established class II¯ tumors by a mechanism involving CD4+ cells. Previous studies have shown that expression of the immune co-stimulator B7.1 can induce the rejection of some, but not all, murine tumors. In this study, we show that expression of B7.1 by itself has no effect on the tumorigenicity of NC murine adenocarcinoma cells. Similarly, expression of interleukin-2 (IL-2) alone has little effect on the tumorigenicity of these cells. By contrast, the combined expression of B7.1 and IL-2 substantially reduces the tumorigenicity of NC cells, and irradiated NC/B7.1/IL-2 cells are able to induce the rejection of previously established NC tumors. These results suggest a much greater therapeutic potential for tumor cell vaccines that express both B7.1 and IL-2 rather than either of the immune modulators alone.